As an important immunosuppressive factor, PD-L1 is a predictive biomarker for cancer immunotherapy and plays a crucial role in the malignant progression of different cancers, including but not limited to MM, OC, RCC, BC, as well as NSCLC [92–94]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.